FDA approval of a generic intravenous sugammadex sodium formulation; does not report clinical trial outcomes or comparative efficacy data.
Reported
Approval date2026-07-28
Application numberANDA218814
Formulation 1 strength500 mg base/5 mL
Loading
Company
1 development in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of a generic intravenous sugammadex sodium formulation; does not report clinical trial outcomes or comparative efficacy data.